Anemia of chronic disease future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Badria Munir (talk | contribs) No edit summary |
Badria Munir (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
'''Investigational Therapy''': | '''Investigational Therapy''': | ||
* Use of agents that alter the function of hepcidin such as hepcidin antagonists.<ref name="pmid24186312">{{cite journal |vauthors=Fung E, Nemeth E |title=Manipulation of the hepcidin pathway for therapeutic purposes |journal=Haematologica |volume=98 |issue=11 |pages=1667–76 |date=November 2013 |pmid=24186312 |pmc=3815165 |doi=10.3324/haematol.2013.084624 |url=}}</ref> | * Use of agents that alter the function of [[hepcidin]] such as [[hepcidin]] antagonists.<ref name="pmid24186312">{{cite journal |vauthors=Fung E, Nemeth E |title=Manipulation of the hepcidin pathway for therapeutic purposes |journal=Haematologica |volume=98 |issue=11 |pages=1667–76 |date=November 2013 |pmid=24186312 |pmc=3815165 |doi=10.3324/haematol.2013.084624 |url=}}</ref> | ||
* Agents that alter the function of hepcidin receptor (ferroportin) in order to manage the level of hepcidin.<ref name="pmid24398330">{{cite journal |vauthors=Poli M, Asperti M, Naggi A, Campostrini N, Girelli D, Corbella M, Benzi M, Besson-Fournier C, Coppin H, Maccarinelli F, Finazzi D, Arosio P |title=Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo |journal=Blood |volume=123 |issue=10 |pages=1564–73 |date=March 2014 |pmid=24398330 |pmc=3945865 |doi=10.1182/blood-2013-07-515221 |url=}}</ref> | * Agents that alter the function of [[hepcidin]] receptor ([[ferroportin]]) in order to manage the level of [[hepcidin]].<ref name="pmid24398330">{{cite journal |vauthors=Poli M, Asperti M, Naggi A, Campostrini N, Girelli D, Corbella M, Benzi M, Besson-Fournier C, Coppin H, Maccarinelli F, Finazzi D, Arosio P |title=Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo |journal=Blood |volume=123 |issue=10 |pages=1564–73 |date=March 2014 |pmid=24398330 |pmc=3945865 |doi=10.1182/blood-2013-07-515221 |url=}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 15:11, 5 October 2018
|
Anemia of chronic disease Microchapters | |
|
Differentiating Anemia of chronic disease from other Diseases | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Case Studies | |
|
Anemia of chronic disease future or investigational therapies On the Web | |
|
American Roentgen Ray Society Images of Anemia of chronic disease future or investigational therapies | |
|
FDA on Anemia of chronic disease future or investigational therapies | |
|
CDC on Anemia of chronic disease future or investigational therapies | |
|
Anemia of chronic disease future or investigational therapies in the news | |
|
Blogs on Anemia of chronic disease future or investigational therapies | |
|
Risk calculators and risk factors for Anemia of chronic disease future or investigational therapies | |
Investigational Therapy:
- Use of agents that alter the function of hepcidin such as hepcidin antagonists.[1]
- Agents that alter the function of hepcidin receptor (ferroportin) in order to manage the level of hepcidin.[2]
References
- ↑ Fung E, Nemeth E (November 2013). "Manipulation of the hepcidin pathway for therapeutic purposes". Haematologica. 98 (11): 1667–76. doi:10.3324/haematol.2013.084624. PMC 3815165. PMID 24186312.
- ↑ Poli M, Asperti M, Naggi A, Campostrini N, Girelli D, Corbella M, Benzi M, Besson-Fournier C, Coppin H, Maccarinelli F, Finazzi D, Arosio P (March 2014). "Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo". Blood. 123 (10): 1564–73. doi:10.1182/blood-2013-07-515221. PMC 3945865. PMID 24398330.